Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

MGMT Protein Expression and Promoter Methylation in Glioblastoma Survival: a systematic review and meta-analysis.

Created on 13 Nov 2026

Authors

Mike van Heumen, Victoria Schmelzer, Lukas Panayotopoulos, Karlijn Hermans, Léon C van Kempen, Martinus P G Broen, Jan Beckersvordersandforth, Koos E Hovinga, Daniëlle B P Eekers, Annette Compter, Tom J Snijders, Ann Hoeben, Marc Vooijs

Published in

Neuro-oncology. Nov 13, 2026. Epub Nov 13, 2026.

Abstract

Glioblastoma is the most common malignant brain tumor in adults. Methylation of the O6-methylguanine-DNA methyltransferase (MGMT) promoter is the only clinically used biomarker predicting response to alkylating agents such as temozolomide and is associated with improved survival. However, its predictive accuracy is limited by an intermediate gray zone and variability in assessment methods. To reduce overtreatment of patients, improved stratification strategies are needed, potentially through integration of additional biomarkers such as MGMT protein expression.
We performed a systematic review to evaluate studies comparing the prognostic value for progression-free survival and overall survival of MGMT promoter methylation and MGMT protein expression in glioblastoma patients treated with temozolomide, including 33 independent cohorts with a total of 4,691 patients. We searched three databases up to May 2025. Risk of bias was assessed with a modified Quips tool.
Methylation-specific PCR and pyrosequencing indicated stronger prognostic value than immunohistochemical assessment of MGMT protein expression with hazard ratios (HRs) of 2.07 (95%CI 1.61-2.66), 2.13 (95%CI 1.64-2.75), and 1.50 (95%CI 1.26-1.79), respectively. An inverse correlation between MGMT promoter methylation and protein expression was observed in only 52% of assessed studies, suggesting that promoter methylation and protein expression may contribute independently to prognosis.
Substantial variability in methylation assays and protein cut-offs underscores the need for methodological harmonization in future studies and clinical practice. Integration of MGMT protein expression with promoter methylation refines identification of primary temozolomide-resistant tumors and supports the debate of withholding temozolomide in patients unlikely to benefit.

PMID:
43021570
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement